{
    "id": 7815,
    "fullName": "CSF1R positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "CSF1R positive indicates the presence of the CSF1R gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 1436,
        "geneSymbol": "CSF1R",
        "terms": [
            "CSF1R",
            "BANDDOS",
            "C-FMS",
            "CD115",
            "CSF-1R",
            "CSFR",
            "FIM2",
            "FMS",
            "HDLS",
            "M-CSF-R"
        ]
    },
    "variant": "positive",
    "createDate": "06/18/2015",
    "updateDate": "05/27/2016",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 2453,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nexavar (sorafenib) inhibited CSF1R phosphorylation and induced apoptosis in Hodgkin's lymphoma cells in culture (PMID: 21517818)",
            "molecularProfile": {
                "id": 7709,
                "profileName": "CSF1R positive"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 8567,
                "name": "Hodgkin's lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3071,
                    "pubMedId": 21517818,
                    "title": "BAY 43-9006/Sorafenib blocks CSF1R activity and induces apoptosis in various classical Hodgkin lymphoma cell lines.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21517818"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6066,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "In multiple clinical studies, elevated levels of CSF1R expression were associated with a worse survival in patients with Hodgkin's lymphoma (PMID: 24619759, PMID: 26066800, PMID: 22955918).",
            "molecularProfile": {
                "id": 7709,
                "profileName": "CSF1R positive"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 8567,
                "name": "Hodgkin's lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5269,
                    "pubMedId": 24619759,
                    "title": "CSF-1R expression in tumor-associated macrophages is associated with worse prognosis in classical Hodgkin lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24619759"
                },
                {
                    "id": 5270,
                    "pubMedId": 26066800,
                    "title": "CSF1R Protein Expression in Reactive Lymphoid Tissues and Lymphoma: Its Relevance in Classical Hodgkin Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26066800"
                },
                {
                    "id": 5271,
                    "pubMedId": 22955918,
                    "title": "Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22955918"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16863,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NMS-P088 inhibited proliferation of Csf1r-expressing blasts derived from chronic myelomonocytic leukemia patients (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1324).",
            "molecularProfile": {
                "id": 7709,
                "profileName": "CSF1R positive"
            },
            "therapy": {
                "id": 8211,
                "therapyName": "NMS-P088",
                "synonyms": null
            },
            "indication": {
                "id": 80188,
                "name": "chronic myelomonocytic leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14983,
                    "pubMedId": null,
                    "title": "NMS-P088, a novel FLT3, KIT and CSF1R inhibitor, is a promising clinical candidate for AML and CMML treatment.",
                    "url": "https://www.aacr.org/Documents/AACR_2019_Proceedings.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6075,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma mouse model harboring BRAF V600E treated with Zelboraf (vemurafenib) demonstrated a greater drug induced sensitivity when treatment was combined with PLX3397, resulting in increased infiltration of lymphocytes via Csf1r inhibition and elevated antitumor activity (PMID: 25939769).",
            "molecularProfile": {
                "id": 22385,
                "profileName": "BRAF V600E CSF1R pos"
            },
            "therapy": {
                "id": 1339,
                "therapyName": "Pexidartinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5274,
                    "pubMedId": 25939769,
                    "title": "Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25939769"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 7709,
            "profileName": "CSF1R positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22385,
            "profileName": "BRAF V600E CSF1R pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}